TRIAL DETAIL

Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor

Drug:	Imatinib
Trial Name:	Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
NCT#:	NCT01267695
Conditions:	Gastrointestinal Stromal Tumor
Status:	Completed
Phase:	2	Start Date 04/01/2010	Age of Trial (yrs) 14.7
Treatment Phase:	Neoadjuvant
Drug Category:	KIT/PDGFRA inhibitor
Strategy:	Block KIT
Trial Type:	Specifically GIST and only GIST
Other Protocol IDs:	WJP-320.6700.09010
Sponsor:	Peking University
Patient Contact:	Jiafu Ji, master 86-10-88196048 dr.jijiafu@gmail.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:	Oral
Trial Notes:	Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Perioperative imatinib mesylate may shrink the tumor and may reduce the chance of relapse after surgery. This phase II trial is studying the effectiveness of perioperative imatinib mesylate in treating patients with locally advanced gastrointestinal stromal tumor. Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.

Name	Address	City	State	Zip	Country